MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'gene mutations'. Sat, 03 Sep 2011 02:49:54 +0100 http://www.medworm.com/index.php?rid=5159670&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F08%2F22%2Fparp-inhibitor-olaparib-has-activity-in-high-grade-serous-ovarian-cancer-without-inherited-brca1-or-brca2-gene-mutations%2F Researchers affiliated with the British Columbia Cancer Agency reported Phase 2 clinical study results indicating that advanced ovarian cancer, with and without germline (inherited) BRCA 1 or BRCA 2 gene mutations, responded to treatment with the PARP inhibitor olaparib. The Phase 2 study results were published online in the August 21 edition of The Lancet [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=5159670 Mon, 22 Aug 2011 18:39:54 +0100 5159670 http://www.medworm.com/index.php?rid=5140181&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F08%2F18%2Fu-k-researchers-launch-clinical-trial-of-mercaptopurine-6-mp-in-women-with-hereditary-breast-and-ovarian-cancer%2F A Cancer Research UK-funded clinical trial of a new drug for patients with advanced breast or ovarian cancer due to inherited BRCA gene mutations has been launched at the Experimental Cancer Medicine Centre at the University of Oxford. A Cancer Research UK-funded trial of a new drug for patients with advanced breast or ovarian cancer [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=5140181 Thu, 18 Aug 2011 21:07:56 +0100 5140181 http://www.medworm.com/index.php?rid=4902644&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F04%2F2011-asco-women-with-brca-gene-mutations-can-take-hormone-replacement-therapy-safely-after-ovary-removal%2F Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania Women with the BRCA1 or BRCA2 gene mutations, which are linked [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4902644 Sat, 04 Jun 2011 20:16:50 +0100 4902644 http://www.medworm.com/index.php?rid=4841887&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2Fasco-2011-maintenance-therapy-with-parp-inhibitors-could-play-important-role-in-treatment-of-recurrent-ovarian-cancer%2F A randomized phase II clinical trial showed that the oral PARP inhibitor drug olaparib (AZD2281), given after chemotherapy, improved progression-free survival in women with the most common type of recurrent ovarian cancer. ASCO Releases Studies From Upcoming Annual Meeting – Important Advances in Targeted Therapies, Screening, and Personalized Medicine The American Society of Clinical Oncology (ASCO) today [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841887 Thu, 19 May 2011 18:03:58 +0100 4841887 http://www.medworm.com/index.php?rid=4349659&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F01%2F14%2Fcaris-life-sciences-launches-molecular-profiling-service-for-ovarian-cancer-patients%2F Caris Life Sciences announces the launch of a new molecular profiling service for ovarian cancer patients Caris Life Sciences, Inc. (Caris), a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, announced the launch of a new, Caris Target Now™ molecular profile [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4349659 Fri, 14 Jan 2011 22:11:53 +0100 4349659 http://www.medworm.com/index.php?rid=4159429&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F11%2F11%2Fnew-assay-test-predicts-that-50-of-ovarian-cancers-will-respond-to-in-vitro-parp-inhibition%2F U.K. researchers develop a new test that could be used to select ovarian cancer patients who will benefit from a new class of drugs called “PARP inhibitors.” U.K. researchers have developed a new test that could be used to select which patients with ovarian cancer will benefit from a new class of drugs called “PARP [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4159429 Fri, 12 Nov 2010 00:19:19 +0100 4159429 http://www.medworm.com/index.php?rid=3740787&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F07%2F09%2Fesmo-clinical-practice-guidelines-regarding-brca-gene-mutations-ovarian-cancer-supportive-cancer-care%2F The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology, and promoting a multidisciplinary approach to cancer treatment and care. …  The ESMO Clinical Practice Guidelines include coverage of  (i) BRCA gene mutations in breast and ovarian cancer, (ii) gynecologic tumors, and (iii) supportive [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3740787 Fri, 09 Jul 2010 22:27:51 +0100 3740787 http://www.medworm.com/index.php?rid=3508396&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F04%2F26%2Fon-the-path-to-early-detection-fox-chase-sloan-kettering-researchers-identify-early-ovarian-cancers%2F Researchers at the Fox Chase Cancer Center and the Memorial Sloan-Kettering Cancer Center discover early tumors and precancerous lesions in cysts that fold into the ovary from its surface, called inclusion cysts. “This is the first study giving very strong evidence that a substantial number of ovarian cancers arise in inclusion cysts and that there [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3508396 Tue, 27 Apr 2010 04:01:54 +0100 3508396 http://www.medworm.com/index.php?rid=3501683&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F04%2F23%2Fparp-inhibitor-olaparib-benefits-women-with-inherited-ovarian-cancer-based-upon-platinum-drug-sensitivity%2F Olaparib (AZD2281), a new type of cancer drug known as a “PARP inhibitor,” produced promising results in patients with platinum-refractory, platinum-resistant, and platinum-sensitive ovarian cancer linked to an inherited BRCA1 or BRCA2 gene mutation. A new type of cancer drug — known as a “PARP inhibitor” — produced promising results in patients with ovarian cancer linked [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3501683 Sat, 24 Apr 2010 00:38:57 +0100 3501683 http://www.medworm.com/index.php?rid=3494508&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F04%2F21%2Fresearchers-identify-a-new-breast-ovarian-cancer-susceptibility-gene%2F German researchers identify a new breast and ovarian cancer susceptibility gene known as “RAD51C.”  The risk for breast cancer in women with the RAD51C mutation is 60 to 80 percent, while the risk for ovarian cancer is 20 to 40 percent. The discovery 15 years ago that the genes BRCA1 and BRCA2 confer high risks for [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3494508 Thu, 22 Apr 2010 03:46:29 +0100 3494508 http://www.medworm.com/index.php?rid=3153592&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F01%2F07%2Felevated-proteins-may-warn-of-ovarian-cancer-but-sufficient-lead-time-predictive-value-still-lacking%2F Fred Hutchinson Cancer Center researchers discovered that concentrations of the serum biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3153592 Thu, 07 Jan 2010 22:22:08 +0100 3153592 http://www.medworm.com/index.php?rid=2725213&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F08%2F21%2Fua-research-team-designing-holographic-imaging-system-for-ovarian-cancer%2F University of Arizona researchers Jennifer Barton and Ray Kostuk have received a five-year, $2.4 million grant from the National Institutes of Health to build the instrument that they hope will one day be used to monitor women at high risk for ovarian cancer. Two University of Arizona [UA] researchers have formed a research team to [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2725213 Sat, 22 Aug 2009 02:26:23 +0100 2725213 http://www.medworm.com/index.php?rid=2702485&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F08%2F14%2Fwomen-often-opt-to-surgically-remove-their-breasts-ovaries-to-reduce-cancer-risk%2F Many women at high risk for breast or ovarian cancer are choosing to undergo surgery as a precautionary measure to decrease their cancer risk, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. PHILADELPHIA – Many women at high risk for breast or ovarian cancer are [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2702485 Fri, 14 Aug 2009 21:45:23 +0100 2702485 http://www.medworm.com/index.php?rid=2662627&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F08%2F01%2Fnew-study-shows-four-year-window-for-early-detection-of-ovarian-cancer%2F A new study by Howard Hughes Medical Institute researchers shows that most early stage ovarian tumors exist for years at a size that is a thousand times smaller than existing tests can detect reliably.  But the researchers say their findings also point to new opportunities for detecting ovarian cancer—a roughly four-year window during which most [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2662627 Sat, 01 Aug 2009 22:45:36 +0100 2662627 http://www.medworm.com/index.php?rid=2649245&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F07%2F28%2Fvox-populi-libby-well-be-missing-you%2F Vox Populi:  Libby, We’ll Be Missing You. Dear Libby, One year ago today, you left us after an extended battle with ovarian cancer.  You are missed as a wife, a daughter, a sister, an aunt and a cousin.  You were, and continue to be, a very special family member to your loved ones who remain behind.  [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2649245 Tue, 28 Jul 2009 21:49:25 +0100 2649245 http://www.medworm.com/index.php?rid=2442555&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F24%2Fgenetic-testing-for-hereditary-breast-and-ovarian-cancers-greatly-underutilized-by-high-risk-women%2F A women’s lifetime breast cancer risk is approximately 13 percent, and her ovarian cancer risk is less than 2 percent.  But women with BRCA1 (BReast CAncer 1) or BRCA2 (BReast CAncer 2) gene mutations may be 3 to 7 times more likely to develop breast cancer, and 9 to 30 times more likely to develop [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2442555 Mon, 25 May 2009 01:03:00 +0100 2442555 http://www.medworm.com/index.php?rid=2415712&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F17%2Fsymptoms-of-ovarian-cancer-remain-relatively-stabile-over-time-as-reported-by-high-risk-women%2F Researchers from the Fred Hutchinson Cancer Research Center reported recently that symptoms of ovarian cancer tend to be relatively stable over time for women who are at increased risk of ovarian cancer based upon family history of cancer or BRCA 1/2 gene mutation. Researchers from the Fred Hutchinson Cancer Research Center, located in Seattle, Washington, recently [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2415712 Mon, 18 May 2009 02:08:18 +0100 2415712 http://www.medworm.com/index.php?rid=2381062&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F30%2Fwomen-of-diverse-ethnic-ancestry-have-similar-risk-of-carrying-brca-mutations-as-those-with-western-european-ancestry%2F ” …The study, performed by researchers at Philadelphia’s Fox Chase Cancer Center and Myriad Genetics, Inc., analyzed the prevalence of BRCA1/BRCA2 gene mutations in patients of different ethnicities at risk for hereditary breast and ovarian cancer. The study included test results of 46,276 women during the ten-year period from 1996 to 2006. Study subjects encompassed [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2381062 Thu, 30 Apr 2009 23:12:40 +0100 2381062 http://www.medworm.com/index.php?rid=2299065&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F24%2Froutine-screening-for-hereditary-breast-and-ovarian-cancer-recommended-by-acog-sgo%2F Evaluating a patient’s risk of hereditary breast and ovarian cancer syndrome is an important first step in cancer prevention and early detection and should be a routine part of ob-gyn practice. Those who are likely to have the syndrome should be referred for further assessment to a clinician with expertise in genetics, according to a [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2299065 Wed, 25 Mar 2009 03:55:32 +0100 2299065 http://www.medworm.com/index.php?rid=2268016&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F14%2Fmassachusetts-general-hospital-cancer-center-to-genetically-profile-all-patient-tumors%2F “The Massachusetts General Hospital Cancer Center has recently opened a new Translational Research Laboratory that will uncover the genetic codes and gene mutations from almost all of its cancer patients. … By embarking on such an ambitious approach, Cancer Center pathologists and oncologists hope to gather specific information about tumor properties that will lead to [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2268016 Sun, 15 Mar 2009 02:59:44 +0100 2268016 http://www.medworm.com/index.php?rid=2218535&cid=t_129554_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F02%2F26%2Ftwo-studies-address-risk-reduction-screening-for-brca-12-gene-mutation-carriers%2F “Prophylactic salpingo-oophorectomy - removal of the ovaries and fallopian tubes–reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube cancer by approximately 80 percent in women who carry a mutation in the BRCA1 or BRCA2 gene, researchers report in the January 13 online issue of the [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2218535 Thu, 26 Feb 2009 22:56:50 +0100 2218535 http://www.medworm.com/index.php?rid=2035943&cid=t_129554_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F483040604%2F Drugmakers may be forced to change prescribing info on cancer meds already being sold in the US to advise patients that some treatments won’t work in people who carry certain genes, Bloomberg News writes. Prescribing drugs on the basis of genetic profiles can limit use of medicines to patients who will benefit most and increase their safe use, FDA staffers wrote in briefing materials for an advisory committee meeting on December 16. The change may also hinder sales of drugs that previously might have been given to more people, just on the chance they may work. The meeting is being held to discuss whether to recommend that doctors screen patients for the so-called KRAS gene mutation before prescribing Erbitux, which is marketed by Lilly and Bristol-Myers Squibb, and Amgen’s Vectib... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2035943 Fri, 12 Dec 2008 21:07:51 +0100 2035943 http://www.medworm.com/index.php?rid=716527&cid=t_129554_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F07%2F05%2Fspecific-gene-mutation-connected-directly-to-cancer%2F Filed under: All CancersIn what is being called a "major breakthrough in cancer treatment," bioscience researchers from a genomics research institute and the pharmaceutical company Eli Lilly have discovered a recurring mutation in a human gene when breast, colorectal and ovarian cancer is detected.With such detection, experts theorize that the impact on cancer treatment will be significant. The optimism comes mostly from the pharmaceutical end, where designer drugs based on genetic principles may be able to be used in being tailored to attack specific kinds of cancer in a specific kind of patient.In other words, the age of customized drugs -- to each person and that person's cancer type, individually -- may soon be upon us.Read | Permalink | Email this | Linki... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=716527 Thu, 05 Jul 2007 04:00:00 +0100 716527